Ozempic in a Pill. Here's the Catch.

The FDA just approved the first true "Ozempic pill," orforglipron, sold as Foundayo. But it isn't actually Ozempic. In this video I break down exactly what this pill does inside your body, how scientists finally got a GLP-1 drug to survive your stomach, and the one catch that decides whether it's right for you. 📘 FREE GLP-1 Companion Guide (what to understand before you start): https://www.draminhedayat.com/glp1_co... (If the link is not working, copy and paste it in your browser) Whether you're considering the pill, already on Ozempic, Wegovy, Mounjaro, or Zepbound, or you just want to understand the science, this is the level of detail most patients never get in a 15-minute clinic visit. WHAT YOU'LL LEARN Why orforglipron is not the same molecule as Ozempic The 20-year problem that forced these drugs to be injectable The Gila monster discovery behind every GLP-1 drug on the market How they engineered a pill that survives stomach acid What the Phase 3 ATTAIN-1 trial actually showed, and the honest number The real catch: more accessible, but not more effective than the shots How to tolerate it, and the one thing this pill can't do for you ▶️ Go deeper with the Inner Circle, my community for people who want to apply the science, not just watch it: https://getuninflamed.com CHAPTERS  ​00:00 Is the New Ozempic Pill Dangerous? 03:08 How GLP-1 Weight Loss Drugs Actually Work 04:50 Why Old GLP-1s Required Injections 06:02 How the New Daily Weight Loss Pill Works 07:42 The Muscle Loss Trap: Why Your Scale is Lying 11:08 Ozempic Face & Muscle Wasting Explained 12:06 Strategy 1: The Protein Threshold (mTOR) 14:14 Strategy 2: Resistance Training & Mechanical Tension 16:20 Strategy 3: Gut Health & Dosage Titration 17:59 Rebound Weight Gain: What Happens When You Stop? 19:51 Final Thoughts: Protecting Your Metabolism CONNECT YouTube: @draminhedayat Website: https://www.draminhedayat.com Community: https://getuninflamed.com ⚕️ DISCLAIMER I'm a physician but I am not your physician. This video is medical education, not medical advice, and it does not create a doctor-patient relationship. Any decision about orforglipron or any medication should be made with your own doctor who knows your individual history. I have no financial relationship with Eli Lilly, Novo Nordisk, or any pharmaceutical company, and this video is not sponsored. The Inner Circle is an educational community and does not provide medical care. REFERENCES Orforglipron (brand name Foundayo) was approved by the U.S. FDA on April 1, 2026 for chronic weight management. 1. Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774. 2. Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. doi:10.1056/NEJMoa2416394. 3. Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. #Ozempic #GLP1 #WeightLoss #OzempicPill #Orforglipron #Foundayo #Zepbound #Mounjaro #Wegovy #Tirzepatide #Semaglutide #MetabolicHealth